Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7623-7632

  Herschhorn, Alon ^a,b   Marasco, Wayne A ^b   Hizi, Amnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FAS LIGAND; HLA C ANTIGEN; NEF PROTEIN;

ARTICLE; BINDING AFFINITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGEN PRESENTATION; EPITOPES, T-LYMPHOCYTE; HIV ANTIBODIES; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; JURKAT CELLS; LENTIVIRUSES, PRIMATE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650650781     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001561     Document Type: Article

References (43)

1. Collins, K. L., B. K. Chen, S. A. Kalams, B. D. Walker, and D. Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397-401.
2. López, D., B. C. Gil-Torregrosa, C. Bergmann, and M. Del Val. 2000. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation. J. Immunol. 164:5070-5077.
3. Kuby, J. 1997. Immunology. W. H. Freeman and Company, New York.
4. *201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J. Exp. Med. 199:1367-1377.
5. Denkberg, G., A. Lev, L. Eisenbach, I. Benhar, and Y. Reiter. 2003. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171:2197-2207.
6. Bonaparte, M. I., and E. Barker. 2004. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104:2087-2094.
7. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, and D. Baltimore. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661-671.
8. Specht, A., M. Q. DeGottardi, M. Schindler, B. Hahn, D. T. Evans, and F. Kirchhoff. 2008. Selective downmodulation of HLA-A and-B by Nef alleles from different groups of primate lentiviruses. Virology 373:229-237.
9. Kawashima, Y., K. Pfafferott, J. Frater, P. Matthews, R. Payne, M. Addo, H. Gatanaga, M. Fujiwara, A. Hachiya, H. Koizumi, et al. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645.
10. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
11. Makadzange, A. T., G. Gillespie, T. Dong, P. Kiama, J. Bwayo, J. Kimani, F. Plummer, P. Easterbrook, and S. L. Rowland-Jones. 2010. Characterization of an HLA-C-restricted CTL response in chronic HIV infection. Eur. J. Immunol. 40:1036-1041.
12. Currier, J. R., U. Visawapoka, S. Tovanabutra, C. J. Mason, D. L. Birx, F. E. McCutchan, and J. H. Cox. 2006. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol. 7:8.
13. Fellay, J., K. V. Shianna, D. Ge, S. Colombo, B. Ledergerber, M. Weale, K. Zhang, C. Gumbs, A. Castagna, A. Cossarizza, et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-947.
14. Thomas, R., R. Apps, Y. Qi, X. Gao, V. Male, C. O'Huigin, G. O'Connor, D. Ge, J. Fellay, J. N. Martin, et al. 2009. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat. Genet. 41:1290-1294.
15. Specht, A., A. Telenti, R. Martinez, J. Fellay, E. Bailes, D. T. Evans, M. Carrington, B. H. Hahn, D. B. Goldstein, and F. Kirchhoff. 2010. Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J. Virol. 84:7300-7311.
16. Middleton, D., L. Menchaca, H. Rood, and R. Komerofsky. 2003. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61:403-407.
17. Frahm, N., B. T. Korber, C. M. Adams, J. J. Szinger, R. Draenert, M. M. Addo, M. E. Feeney, K. Yusim, K. Sango, N. V. Brown, et al. 2004. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 78:2187-2200.
18. Gray, C. M., M. Mlotshwa, C. Riou, T. Mathebula, D. de Assis Rosa, T. Mashishi, C. Seoighe, N. Ngandu, F. van Loggerenberg, L. Morris, et al; CAPRISA 002 Acute Infection Study Team. 2009. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J. Virol. 83:470-478.
19. Yu, X. G., M. M. Addo, E. S. Rosenberg, W. R. Rodriguez, P. K. Lee, C. A. Fitzpatrick, M. N. Johnston, D. Strick, P. J. Goulder, B. D. Walker, and M. Altfeld. 2002. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J. Virol. 76:8690-8701.
20. Anderson, S., D. C. Shugars, R. Swanstrom, and J. V. Garcia. 1993. Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J. Virol. 67:4923-4931.
21. Kirchhoff, F., P. J. Easterbrook, N. Douglas, M. Troop, T. C. Greenough, J. Weber, S. Carl, J. L. Sullivan, and R. S. Daniels. 1999. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J. Virol. 73:5497-5508.
22. Adnan, S., A. Balamurugan, A. Trocha, M. S. Bennett, H. L. Ng, A. Ali, C. Brander, and O. O. Yang. 2006. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 108:3414-3419.
23. Goonetilleke, N., M. K. Liu, J. F. Salazar-Gonzalez, G. Ferrari, E. Giorgi, V. V. Ganusov, B. F. Keele, G. H. Learn, E. L. Turnbull, M. G. Salazar, et al; CHAVI Clinical Core B. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
24. Nehete, P. N., D. E. Lewis, D. N. Tang, M. S. Pollack, and K. J. Sastry. 1998. Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus. Viral Immunol. 11:119-129.
25. Falk, K., O. Rötzschke, B. Grahovac, D. Schendel, S. Stevanović, V. Gnau, G. Jung, J. L. Strominger, and H. G. Rammensee. 1993. Allele-specific peptide ligand motifs of HLA-C molecules. Proc. Natl. Acad. Sci. USA 90:12005-12009. (Pubitemid 24008769)
26. Maurer, K., E. G. Harrer, A. Goldwich, K. Eismann, S. Bergmann, M. Schmitt-Haendle, B. Spriewald, S. M. Mueller, T. Harrer; German Competence Network for HIV/AIDS. 2008. Role of cytotoxic T-lymphocyte-mediated immune selection in a dominant human leukocyte antigen-B8-restricted cytotoxic T-lymphocyte epitope in Nef. J. Acquir. Immune Defic. Syndr. 48:133-141.
27. Neri, D., A. Pini, and A. Nissim. 1998. Antibodies from phage display libraries as immunochemical reagents. Methods Mol. Biol. 80:475-500.
28. Herschhorn, A., A. Admon, and A. Hizi. 2003. Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1. Biochim. Biophys. Acta 1648:154-163. (Pubitemid 38234617)
29. Jordan, M., A. Schallhorn, and F. M. Wurm. 1996. Transfecting mammalian cells: optimization of critical parameters affecting calciumphosphate precipitate formation. Nucleic Acids Res. 24:596-601.
30. Herschhorn, A., L. Lerman, M. Weitman, I. O. Gleenberg, A. Nudelman, and A. Hizi. 2007. De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants. J. Med. Chem. 50:2370-2384.
31. Fang, J., J. J. Qian, S. Yi, T. C. Harding, G. H. Tu, M. Van Roey, and K. Jooss. 2005. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23:584-590.
32. Taube, R., Q. Zhu, C. Xu, F. Diaz-Griffero, J. Sui, E. Kamau, M. Dwyer, D. Aird, and W. A. Marasco. 2008. Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS ONE 3: e3181.
33. Herschhorn, A., and A. Hizi. 2008. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. J. Med. Chem. 51:5702-5713.
34. Naldini, L., U. Blömer, F. H. Gage, D. Trono, and I. M. Verma. 1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93:11382-11388.
35. Weber, K., U. Bartsch, C. Stocking, and B. Fehse. 2008. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol. Ther. 16:698-706.
36. Marasco, W. A. 2001. Intrabodies as antiviral agents. Curr. Top. Microbiol. Immunol. 260:247-270.
37. Griffiths, A. D., S. C. Williams, O. Hartley, I. M. Tomlinson, P. Waterhouse, W. L. Crosby, R. E. Kontermann, P. T. Jones, N. M. Low, T. J. Allison, et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:3245-3260.
38. Shimizu, Y., and R. DeMars. 1989. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 142:3320-3328.
39. Carreno, B. M., and T. H. Hansen. 1994. Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. Eur. J. Immunol. 24:1285-1292.
40. Bremer, E., B. ten Cate, D. F. Samplonius, L. F. de Leij, and W. Helfrich. 2006. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107:2863-2870.
41. Peter, M. E., and P. H. Krammer. 2003. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
42. Brumme, Z. L., C. J. Brumme, D. Heckerman, B. T. Korber, M. Daniels, J. Carlson, C. Kadie, T. Bhattacharya, C. Chui, J. Szinger, et al. 2007. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 3: e94.
43. Malhotra, U., F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. McElrath. 2007. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J. Virol. 81:5225-5237.